文献速递细菌感染、耐药与抗菌药物医院感染防控新发突发、热带与寄生虫病

多重β-内酰胺酶突变驱动头孢他啶-阿维巴坦耐药肺炎克雷伯菌医院暴发

Ceftazidime-avibactam-resistant Klebsiella pneumoniae driven by multiple β-lactamase mutations: a hospital outbreak report.
PubMed 文献 · Clin Microbiol Infect · 2026-03-14

该研究对肝胆外科6例住院患者分离的6株头孢他啶-阿维巴坦耐药肺炎克雷伯菌进行耐药表型、基因型及单核苷酸多态性分析,结合分子克隆、酶动力学、接合试验和质粒序列分析。结果显示6株菌单核苷酸多态性均少于6个,提示医院克隆传播;KPC-157不能介导头孢他啶-阿维巴坦耐药,而CTX-M-249(由CTX-M-65发生Ser130Gly和Pro167Ser突变)可介导耐药,因阿维巴坦不能有效抑制该酶活性。

要点

  • 6株耐药菌单核苷酸多态性均少于6个,提示医院内克隆传播。
  • KPC-157不能介导头孢他啶-阿维巴坦耐药。
  • CTX-M-249(CTX-M-65的Ser130Gly和Pro167Ser突变)可介导耐药,阿维巴坦不能有效抑制其活性。

核心结论

  • 报道了产KPC-157的头孢他啶-阿维巴坦耐药肺炎克雷伯菌克隆传播,并首次揭示新bla变体CTX-M-249的耐药机制。

研究设计与样本

  • 从肝胆外科6例住院患者分离6株头孢他啶-阿维巴坦耐药肺炎克雷伯菌,分析耐药表型、基因型及单核苷酸多态性。
  • 通过分子克隆和酶动力学测定阐明耐药机制,用接合试验、S1脉冲场凝胶电泳和质粒序列分析验证耐药可转移性。
  • 用细菌生长曲线和质粒稳定性试验测定适应性。

主要发现

  • 6株菌单核苷酸多态性均少于6个,提示医院克隆传播事件。
  • KPC-157不能介导头孢他啶-阿维巴坦耐药。
  • CTX-M-249由CTX-M-65发生Ser130Gly和Pro167Ser突变而来,可介导头孢他啶-阿维巴坦耐药,因阿维巴坦单独不能有效抑制酶活性。
  • 在头孢他啶-阿维巴坦选择压力下,携带blaCTX-M-249的质粒转移至受体菌。
  • blaCTX-M-65与blaCTX-M-249等位基因共存于不同质粒可能进化为两份blaCTX-M-249,增强对头孢他啶-阿维巴坦的耐药性。

临床怎么用

  • 对头孢他啶-阿维巴坦耐药肺炎克雷伯菌需警惕医院克隆传播,加强感染防控。
  • 关注CTX-M-65向CTX-M-249突变及质粒介导的耐药转移。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study aimed to trace the clonal dissemination of ceftazidime-avibactam-resistant Klebsiella pneumoniae and clarify the complex ceftazidime-avibactam resistance mechanism caused by multiple β-lactamase variants. METHODS: Six ceftazidime-avibactam-resistant K. pneumoniae clinical strains were isolated from six inpatients in the hepatobiliary surgery department. The antimicrobial resistance phenotypes, genotypes and single nucleotide polymorphisms of the strains were analysed. The resistance mechanism of K. pneumoniae strains to ceftazidime-avibactam was clarified through molecular cloning and enzyme kinetic measurement. The transferability of ceftazidime-avibactam resistance in the strains was verified by conjugation test, S1 pulsed field gel electrophoresis and plasmid sequence analysis. Fitness was determined using bacterial growth curves and plasmid stability tests. RESULTS: The number of single nucleotide polymorphisms in all six K. pneumoniae strains was less than six, indicating a nosocomial clonal dissemination incident. K. pneumoniae carbapenemase 157 is unable to mediate resistance to ceftazidime-avibactam. The variant CTX-M-249, which mutated from CTX-M-65 (Ser130Gly and Pro167Ser), could mediate resistance to ceftazidime-avibactam, because avibactam alone could not efficiently inhibit enzyme activity. Under the selective pressure of ceftazidime-avibactam, a plasmid carrying blaCTX-M-249 was transferred into a recipient cell. Based on analysis of the genomic evolution and medical history, the selective pressure exerted by ceftazidime-avibactam during transmission may have contributed to the mutation, replication and truncation of the gene region conferring resistance, especially in the complex evolution of blaCTX-M-65. The coexistence of blaCTX-M-65 and blaCTX-M-249 alleles on different plasmids may have evolved into two copies of blaCTX-M-249, enhancing the resistance to ceftazidime-avibactam. CONCLUSIONS: This study reports the clonal dissemination of K. pneumoniae carbapenemase 157-producing ceftazidime-avibactam-resistant K. pneumoniae strains and reveals the resistance mechanism of a novel bla variant, CTX-M-249 for the first time, to our knowledge. The dissemination of these mutant strains poses an alarm for global infection prevention and control.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Yang W, Tang C, Shi Q, et al. Ceftazidime-avibactam-resistant Klebsiella pneumoniae driven by multiple β-lactamase mutations: a hospital outbreak report. Clin Microbiol Infect. 2026. PMID: 41839419. doi:10.1016/j.cmi.2026.03.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。